The contribution of physics to Nuclear Medicine: physicians’ perspective on future directions by David A Mankoff & Daniel A Pryma
Mankoff and Pryma EJNMMI Physics 2014, 1:5
http://www.ejnmmiphys.com/content/1/1/5OPINION ARTICLE Open AccessThe contribution of physics to Nuclear Medicine:
physicians’ perspective on future directions
David A Mankoff* and Daniel A Pryma* Correspondence:
david.mankoff@uphs.upenn.edu
Division of Nuclear Medicine,
Hospital of the University of
Pennsylvania, University of
Pennsylvania, 116 Donner Building,




Background: Advances in Nuclear Medicine physics enabled the specialty of Nuclear
Medicine and directed research in other aspects of radiotracer imaging, ultimately
leading to Nuclear Medicine’s emergence as an important component of current
medical practice.
Discussion: Nuclear Medicine’s unique ability to characterize in vivo biology without
perturbing it will assure its ongoing role in a practice of medicine increasingly driven
by molecular biology. However, in the future, it is likely that advances in molecular
biology and radiopharmaceutical chemistry will increasingly direct future
developments in Nuclear Medicine physics, rather than relying on physics as the
primary driver of advances in Nuclear Medicine.
Summary: Working hand-in-hand with clinicians, chemists, and biologists, Nuclear
Medicine physicists can greatly enhance the specialty by creating more sensitive and
robust imaging devices, by enabling more facile and sophisticated image analysis to
yield quantitative measures of regional in vivo biology, and by combining the strengths
of radiotracer imaging with other imaging modalities in hybrid devices, with the overall
goal to enhance Nuclear Medicine’s ability to characterize regional in vivo biology.
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From a historical perspective, it can be said that Nuclear Medicine was the direct
result of advances in nuclear physics and their translation to medicine. In many ways,
physics drove the creation of the field, including our abilities to produce radioisotopes
suitable for human use, to capture quantitative data and/or images made possible by
these radioisotopes, and to estimate the quantity of radioactive material that could be
safely and effectively administered to patients for diagnosis and treatment. Advances in
the physics of radioisotope production and radiation detection drove many other as-
pects of Nuclear Medicine research and development - including the type of radiophar-
maceuticals used (99mTc and positron-emitting tracers), the approaches developed for
image acquisition and analysis (dynamic imaging, multi-tracer studies, quantitative im-
aging), and the ability to treat disease using radionuclides (quantitative biodistribution
data, dosimetry) - resulting in a confluence of developments that led to major steps
forward for the specialty. Physics advances helped create Nuclear Medicine and
brought the field to the forefront of medicine as a specialty driven by physical science
and technical innovation.2014 Mankoff and Pryma; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
ttribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
edium, provided the original work is properly credited.
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in molecular biology and precision medicine will drive clinical care [1]. A heightened
understanding of the molecular basis of disease will raise new questions and new de-
mands on imaging to answer those questions. This will, in turn, drive physics advances
in Nuclear Medicine. Nuclear Medicine is no longer defined by the physical nature of
its imaging probes and therapeutic compounds, but rather by its molecular capabilities.
The Society of Nuclear Medicine and Molecular Imaging defines molecular imaging as
‘… the visualization, characterization, and measurement of biological processes at the
molecular and cellular levels in humans and other living systems’ [2]. This definition
emphasizes the molecular and biologic nature of the imaging, rather than its physical
nature. The greatest advantage of radionuclide imaging over other imaging modalities
for molecular imaging lies in its ability to characterize and quantify in vivo biologic
processes at the molecular level without perturbing them. This capability defines the
essence of Nuclear Medicine and assures its place in the future of molecular medicine,
and it will drive the physics needs of the specialty in the future.
Discussion
What are the medical needs that will drive Nuclear Medicine physics advances?
Molecularly specific imaging probes to measure regional molecular biology
Increasing sophistication in our ability to characterize genomics and gene expression
will require advances in our ability to measure in vivo molecular processes using highly
sensitive and specific imaging probes. The most sensitive molecular processes - for ex-
ample, enzyme and receptor biochemistry [3,4] - operate at submicromolar physiologic
conditions, often as low as the nanomolar or picomolar range. Radioisotope imaging is
the only current modality that can generate detailed, quantitative human images in this
concentration range without impacting the biologic processes under study. The com-
bination of sensitivity and spatial resolution needed to characterize the regional distri-
bution of molecular radiotracers at or below nanomolar concentrations will be a key
driver of Nuclear Medicine technology. Chemistry advances that generate highly spe-
cific probes will increasingly drive future physics needs, especially with respect to the
need for imaging devices with high system sensitivity and quantitative accuracy. Implicit
in this consideration is the fact that as more and more specific targets are imaged, less
and less output signal will be available.
Quantitative biomarker imaging to characterize disease and direct medical treatment
The rapidly increasing array of disease-specific treatments creates a need for methods
to characterize disease severity (prognosis), predict response to specific therapies
(prediction), and to measure the efficacy of treatment (response). Thus, the focus of ra-
diopharmaceutical imaging will increasingly move away from detection and diagnosis
towards characterization. Biomarkers, namely biologic measures that characterize dis-
ease status or predict disease behavior [1,5], play an ever increasingly important role in
directing highly tailored, individualized treatment [1]. Nuclear Medicine’s ability to
quantify regional in vivo biology underlies its unique strength as a method for measur-
ing quantitative in vivo biomarkers, thereby providing a unique and much-needed tool
for precision medicine [6,7]. This need will drive research leading to improvements in
image quantification and to more sophisticated image analysis. Nuclear Medicine needs
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quantitative regional molecular biology - for example, the rate of flux along a specific
biochemical pathway [8].
Minimizing radiation exposure in diagnostic imaging
There is increasing concern about the risk of low-level radiation exposure arising from diag-
nostic imaging [9]. This is fueled by the ever-increasing use of imaging in clinical care and
concerns that the risk of inducing cancer with diagnostic radiation will counterbalance the
benefits of imaging, especially as patients survive previously lethal diseases that make heavy
use of imaging such as cardiovascular disease and cancer. The availability of methods such
as ultrasound, magnetic resonance imaging (MRI), and optical imaging that do not require
ionizing radiation augments the pressure to reduce radiation exposure from diagnostic im-
aging. These concerns will drive a continued need for getting more and more information
from the smallest possible quantities of radiopharmaceutical and for minimizing the radi-
ation arising from associated tests such as the computed tomography (CT) component of
positron emission tomography (PET)/CT and single photon emission computed tomog-
raphy (SPECT)/CT. Methods that afford simultaneous transmission and emission scanning
by taking advantage of time-of-flight information [10], for example, may permit lower radi-
ation doses and shorter imaging times. Alternative approaches such as PET/MRI [11] or re-
construction methods that jointly estimate emission and attenuation [12] may eliminate
altogether the need for additional radiation exposure to estimate photon attenuation.
The increasing importance of radionuclide therapy, including compounds using alpha emitters
Radionuclide therapy already plays an important role in the treatment of several dis-
eases, including hyperthyroidism and thyroid cancer. The unqualified success of Ra-223
dichloride as a therapeutic radionuclide capable of palliating bone pain and extending
survival in castrate-resistant prostate cancer [13] suggests that radionuclide therapy
using alpha emitters - a highly potent and localized form of radiation - can be effective
in ways that beta emitters cannot [14]. This finding, coupled with our increasing ability
to create highly specific molecular carriers for radionuclide therapy, suggests a bright
future for therapy with alpha emitters and other highly localized radionuclide therapy
agents. However, with increasing potency and localization in radionuclide therapy
comes the need for increased certainty about the quantitative biodistribution of the
therapeutic radiopharmaceutical as well as more sophisticated methods for understanding
and quantifying radiation effects at a microscopic level, i.e., radiation microdosimetry [15].
How will medical needs drive advances in Nuclear Medicine physics?
Radionuclide imaging devices need to be more sensitive
The need to reduce radiation exposure, to accurately quantify regional imaging probe
biodistribution, and to maximize the molecular information derived from imaging will
require improvements in device sensitivity. Most current imaging research has been fo-
cused on detectability, i.e., simply visualizing a finding above background. The evolu-
tion towards accurate quantification of dynamic processes requires the consideration of
not only sensitivity but also temporal resolution. An example is tumor receptor im-
aging, where target expression may be limited, and the quantity of tracer bound to tar-
get will be less than tracers like FDG that are enzymatically trapped [4]. Improvements
Mankoff and Pryma EJNMMI Physics 2014, 1:5 Page 4 of 6
http://www.ejnmmiphys.com/content/1/1/5in image acquisition that reduce imaging uncertainty at low probe concentrations, for
example, improved timing resolution for time-of-flight imaging in PET, will be import-
ant [16]. Increasingly sophisticated and more robust detection systems will decrease in-
strumental uncertainty in the location and timing of detected events and improve the
quality of information that can be obtained from nuclear imaging probes. Tomograph
designs that more fully encompass patient emissions to increase sensitivity may also be
important for some applications, especially those that require whole-body distribution
measures, for example, radiation dosimetry [17]. Increasingly sophisticated image re-
construction methods that extract the most possible information from each detected
radiation event will also contribute to the goal of improved sensitivity [18]. More so-
phisticated and efficient reconstruction algorithms that consider the time course of
tracer concentration [19] and the biologic constraints of the imaged radiopharmaceuti-
cal [20,21] may be particularly helpful in this regard.Radionuclide imaging needs to be quantitative and reproducible
The need for analytic validity of quantitative nuclear imaging measurements [5,22] -
namely accuracy and reproducibility - will direct advances in image generation. This
will include advances in instrumentation and operating procedures designed to support
devices that are quantitatively consistent from day to day and from patient to patient.
In addition, image acquisition and especially image analysis will need to take advantage
of information arising from the time course of uptake to create more robust and mo-
lecularly accurate measures of regional biology [23]. Higher dynamic range in count
rate, enabled for example by detector designs using silicon photomultipliers coupled to
individual crystals [24], will be important for applications that require capturing an ar-
terial input function, such as kinetic modeling. Increasing digital storage capacity and
processing speed will enable further development of list-mode acquisition, image re-
construction, and image processing that can support this goal.Better image and data analysis methods will make it easier for physicians to get the
information they need to direct precision medicine
Advances in computing and the science of molecular imaging analysis will lead to images
more relevant to the needs of molecular medicine. Images of regional radiotracer uptake
should be accompanied by images of key quantitative molecular parameters, made pos-
sible by powerful and user-friendly image analysis software [25]. This software, further-
more, must interface with medical informatics systems to allow the dissemination of these
data to the medical care team. Better methods for obtaining parametric images of tracer
kinetics will support a broader range of Nuclear Medicine biomarkers in clinical medicine.
Improved software for estimating regional radiation dosimetry from quantitative time-
varying biodistribution data will support advances in radionuclide therapy. Advances in
methods for analyzing ‘big data’ that combine increasingly sophisticated molecular im-
aging data with data on tissue genomics and gene expression obtained from tissue sam-
pling will better able to direct individualized medicine.
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imaging will improve our ability to characterize complex in vivo molecular biology in patients
The introduction of hybrid imaging in the form for PET/CT and SPECT/CT has chan-
ged the way Nuclear Medicine is practiced by offering the ability to directly relate re-
gional radiotracer uptake to structural anatomy [26]. More recently, PET/MRI hybrid
devices have been introduced, with early clinical applications driven largely by MRI’s
ability to define anatomy in locations such as the brain and pelvis [11]. Hybrid imaging
will continue to play an important role in Nuclear Medicine, but the future of Nuclear
Medicine as a molecular specialty depends upon the ability to move beyond the mar-
riage of anatomy and tracer distribution to more integrated approaches for quantitative
molecular imaging. Refinements in instrumentation (both in nuclear and non-nuclear
modalities) and improvements in image analysis should allow us to combine the
strengths of the different modalities to better measure in vivo biology. For example, the
combination of hyperpolarized 13C probes [27] and nuclear probes enabled by PET/
MRI should allow us to tackle measurements not possible by either method alone, for
example, characterization of tumor energy metabolism and the relative use of metabolic
substrates such as glucose, lactate, and glutamine [28]. Other modalities such as optical
imaging and MEG may also be possible. These needs will drive further integration of
hybrid imaging modalities not only for image acquisition, but also equally importantly
for image analysis.Summary
The increasing importance of molecular medicine and Nuclear Medicine’s unique ability
to quantify regional in vivo molecular biology assure Nuclear Medicine an ongoing and
significant role in medical science and the practice of medicine. Whereas advances in
physics drove the early creation and evolution of the field of Nuclear Medicine, future de-
velopments will be increasingly guided by advances in molecular biology and molecular
imaging probe chemistry. In turn, advances in the specialty supported by Nuclear Medi-
cine physics will lead to advances in Nuclear Medicine’s ability to measure regional in vivo
biology as an essential component of current and future medical care.Competing interests
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